Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMmunological effects of Avelumab and Aspirin in Triple-Negative Breast Cancer (window trial)
2018-004121-80Phase 2Unknown
- Sponsor
- The Christie
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Avelumab monotherapy with Avelumab + aspirin (2 arms). Status: unknown.
02
Drugs
avelumabaspirin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2018-004121-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004121-80.